
Ooh, Aah, Ouch? Billion-$ Market Feels Your Pain
There were 1,552 brands -including Volini, Omnigel, Dolo and Saridon -to tackle the twinges in 2020; now, there are 2,771.
Consumers are more attentive to alleviating any pain on a more immediate basis, said Shivam Puri, managing director at Cipla Health, which sells the biggest rubefacient brand, Omnigel. Rubefacient are gels and creams for topical application. "Rise of urbanisation and increase in chronic illnesses have led to the need for faster, more convenient formats that are accessible across platforms," said Puri. This is despite medical professionals advising caution on random use of painkillers.
The pain relief category is often lifestyle-driven in urban markets, especially with gym and sports injuries. As a result, the market for analgesics (pain relief medication) and rubefacient more than doubled to Rs 15,905 crore as of May this year, from Rs 6,820 crore as of May 2020, growing at a compounded annual rate of 18%. This is three times faster than overall over-the-counter market growth, which rose at 6% CAGR to Rs 80,000 crore.
Analgesics account for 75% of the pain medication market and within analgesics, paracetamol is the biggest contributor, according to data from market researcher PharmaTrac.
Covid has changed Indians' views on pain management, said Sandeep Verma, head for consumer health business for South Asia at Bayer Pharmaceuticals, which sells Saridon. "A lot of Indians view taking pain relief medication as a sign of weakness or worry about becoming dependent on it. Covid made many of us more aware of how stress, exhaustion, and even mild but recurring pain can chip away at our wellbeing and productivity," he said. "More people are starting to understand that living with untreated pain impacts their quality of life."
Experts said pain management medications are also used to treat inflammation and adjacent issues, widening the need for the pills.
"The analgesic segment that is dominated by paracetamols has been growing at a steady rate of 10%. This is because paracetamol medications are taken alongside other conditions that could include arthritis, any other bacterial or viral infection," said Sheetal Sapale, vice president, commercial, at PharmaTrac.
Nitin Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said lifestyle-related problems - including rising stress levels, lack of sleep and increasing obesity - are reasons for increasing demand for pain medications.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
29 minutes ago
- Time of India
Vertis Infrastructure Trust raises Rs 900 crore via SLB
Vertis Infrastructure Trust , a SEBI-registered infrastructure investment trust (InvIT) has raised Rs 900 crore through a sustainability-linked bond (SLB), marking the largest SLB issuance by an Indian InvIT to date. The proceeds will be used to support the recently awarded TOT-16, a 252-km NH-44 highway corridor in Telangana aimed at enhancing regional connectivity. Explore courses from Top Institutes in Please select course: Select a Course Category Healthcare others Project Management Digital Marketing Degree Data Science Artificial Intelligence Data Analytics Product Management CXO Leadership PGDM Others Finance Cybersecurity Public Policy Management Operations Management Design Thinking MBA MCA healthcare Data Science Technology Skills you'll gain: Financial Analysis in Healthcare Financial Management & Investing Strategic Management in Healthcare Process Design & Analysis Duration: 12 Weeks Indian School of Business Certificate Program in Healthcare Management Starts on Jun 13, 2024 Get Details International Finance Corporation (IFC) has emerged as the anchor investor in the Vertis Infrastructure Trust, which was formerly known as Highways Infrastructure Trust. Earlier this year, Cube Highways Trust (Cube InvIT) secured an investment of Rs 860 crore from the International Finance Corporation (IFC) via an SLB. With IFC as an anchor investor in the above two InvITs, it is expected that there will be enhanced foreign and domestic participation going forward in India's sustainable infrastructure and thematic bonds space. Live Events This SLB, with a 10-year fixed rate, is priced at 7.40%. A sustainability-linked bond (SLB) is a fixed income instrument (bond) where its financial or structural characteristics are tied to predefined sustainability or environmental, social and governance (ESG) objectives.


Time of India
40 minutes ago
- Time of India
Bryan Johnson is planning to shut down or sell his anti-aging startup, says: The problem is now ...
Tech entrepreneur Bryan Johnson who gained fame for his extreme biohacking and longevity pursuits, is currently in the news because of reports that he might either sell or shut down his anti-aging startup. The 47-year-old announced that he does not really need the money, and the company is a "pain in the a**". Bryan Johnson, in the past has shared several scientifically backed anti-aging strategies with daily discipline. Here are five Bryan Johnson anti-aging tips that made news... Multimillionaire Bryan Johnson is known for his highly publicised anti-aging regimen, Project Blueprint. Now an online report suggests that the tech mogul is planning to shut down or sell his longevity-focused startup. As reported by the Wired, Johnson has cited philosophical conflicts and burnout as the reason for the shut down of his anti-aging wellness startup. 'Honestly, I am so close to either shutting it down or selling it,' Johnson told Wired. 'I don't need the money, and it's a pain-in-the-a** company.' Johnson created Blueprint from his personal health regimen . The company sells supplements like a Rs 4,700 'longevity mix' and mushroom-based coffee alternatives. Johnson has also spent around $ 2 million a year on his anti-aging protocol Project Blueprint which recommends strict diets, biometric tracking and plasma transfusions. Why Byran Johnson is planning to shut down or sell his anti-aging startup In an interview with Wired, Johnson expressed that the primary challenge facing his startup is the difficulty in scaling and democratizing access to the complex and personalized anti-aging protocols he has been developing. He also added that the business started to undermine his credibility in the philosophical space. 'It just evolved in a way where I was trying to do people a solid. The problem is now people see the business and give me less credibility on the philosophy side,' he said. 'I will not make that trade-off.' Johnson also said that his focus is shifting towards 'Don't Die'. It is a belief system that the tech entrepreneur launched earlier this year. The belief system was created as a blend of science, ethics and spiritually with an aim of radical life extension. Johnson now believes that the commercial nature of Blueprint acts as a distraction to him. Is Blueprint in trouble Earlier this year it was reported that Blueprint was missing its break-even point by $1 million a month. However, Johnson has denied any kind of financial stress. 'We are break-even, and I've said that publicly many times. We've had profitable months, we've had loss months," he added. AI Masterclass for Students. Upskill Young Ones Today!– Join Now


Time of India
an hour ago
- Time of India
Understanding the New COVID variants: What we all need to know
As reports of new COVID-19 variants surface, public attention is once again on the rise. Search trends have surged by 153% in recent weeks, reflecting not panic, but a growing sense of curiosity and caution. This clearly signals that concern around COVID-19 hasn't vanished—it has evolved. The public is now more proactive, better informed, and prepared to respond to early signs, rather than react after the fact. What's Driving the Surge in Attention? The spike in online search interest is largely centered around a few key areas of concern: ● Symptoms of the new variants ● Severity and transmissibility ● Regional spikes in cases ● Vaccine effectiveness and booster needs This shift in public behavior highlights a positive evolution in health awareness. People are seeking timely updates and diagnostic services even before official guidelines are issued—an encouraging trend compared to the delayed reactions seen during earlier waves. What Are We Seeing Clinically? Our ongoing clinical surveillance shows that the current variants present symptoms similar to previous ones. These include: ● Fever ● Fatigue ● Sore throat ● Severe throat pain or gastrointestinal symptoms (e.g., diarrhoea) in some cases There has been no significant deviation in symptom patterns so far, suggesting that while the new variants are transmissible, they may not be more severe. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Gold Is Surging in 2025 — Smart Traders Are Already In IC Markets Learn More Undo However, continued genomic surveillance and patient monitoring remain essential. How Is Testing Behaviour Changing? A notable trend is the self-driven approach patients are now taking. The most common test-seeking groups include: ● Individuals with symptoms ● Close contacts of confirmed cases ● Patients undergoing follow-up tests 4–5 days after initial diagnosis Additionally, there's growing demand for home sample collection, combining convenience with caution—an indicator of the public's increasing focus on preventive care and early action. What About Vaccination? Despite increased interest in testing, we haven't seen a significant spike in queries about booster doses or re-vaccination yet. Current government advisories remain unchanged, but this may evolve based on variant behavior and case patterns. It's essential to stay updated via official channels for any revised recommendations. Beware of Misinformation At a time when information can spread faster than a virus, misinformation remains a risk. Fortunately, public response today is rooted more in pragmatism than panic. We urge everyone to rely on verified sources such as: ● The Ministry of Health & Family Welfare (MoHFW) ● Trusted public health institutions and diagnostic labs ● Medical experts and peer-reviewed platforms ● Established media channels that cite scientific evidence Conclusion: Stay Informed, Not Alarmed The emergence of new COVID-19 variants should neither be ignored nor feared. The key lies in awareness, vigilance, and timely testing. With a more informed public and well-prepared healthcare systems, we are collectively better positioned to navigate this phase. If you or someone you know is experiencing symptoms, don't delay—get tested. Let's stay prepared. Let's stay responsible. Let's stay ahead. (Dr. Yoginder Pal Singh, Section Head - HLA and Molecular Biology, Agilus Diagnostics)